Residency · Bronx, NY
Sponsored by Montefiore Medical Center/Albert Einstein College of Medicine
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients.
Cell · 2022 · 541 citations · Ari Hakimi
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data.
Nature medicine · 2025 · 122 citations · Ari Hakimi
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
The Lancet. Oncology · 2021 · 402 citations · Alexander Sankin
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
Nature communications · 2021 · 385 citations · Ari Hakimi
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy.
Cancer cell · 2021 · 338 citations · Ari Hakimi
TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025 · 42 citations · David Cahn
Primary Chemoablation of Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer With UGN-102: A Single-Arm, Open-Label, Phase 3 Trial (ENVISION).
The Journal of urology · 2025 · 38 citations · Mark Schoenberg
Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non-Muscle-Invasive Bladder Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · 14 citations · Alexander Sankin